Carmine Therapeutics: Gene Therapy 3.0
Carmine Therapeutics is developing allogeneic, redosable, non-viral gene therapies to treat diseases for which a high unmet medical need exists. The company’s technology harnesses the natural properties of human red blood cells (RBCs) to produce extracellular vesicles (EVs), allowing the delivery of large payloads of genetic material, resulting in high-amplitude, durable transgene expression to replace missing or mutated genes found within the patient. The initial focus is on ocular diseases, including Stargardt disease with plans to expand to cystic fibrosis and neurological diseases in the future.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Carmine’s REGENT® gene therapy delivery platform offers several competitive advantages over both AAV and LNP, including safety, tolerability, expression, durability, and applicability.
- The ability to redose Carmine’s RBCEVs, as well as the flexibility to include multiple payloads beyond the capacity of AAV, while targeting many tropisms, opens the door to the use of gene therapy to target diseases not previously addressable by first- and second-generation approaches.
- Carmine is led by industry veterans with decades of experience in the gene and cell therapy market, along with a world renowned scientific advisory and board of directors.
Click image above to view full announcement.
Carmine Therapeutics was founded in 2019 by EVX Ventures, Professor Harvey Lodish (Whitehead, MIT) and Singaporean Professors Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme, Arris (now Axys) Pharmaceuticals, Millennium Pharmaceuticals and Rubius Therapeutics, is also Chair of the Scientific Advisory Board of Carmine. Headquartered in Cambridge, MA with a research presence in Singapore, Carmine is pioneering next generation gene therapy based on red blood cell extracellular vesicles.
Source: Carmine Therapeutics
Distributed by: Reportable, Inc.
Source: Financial Content
